FINHUB Insights

Eli Lilly Q4 FY25: where the revenue came from and where it went

The whole income statement of Eli Lilly for this quarter, as one diagram: what earned the revenue, and what it went on.

Period
Oct 1 – Dec 31, 2025
Reported
Feb 12, 2026 10-K accession 0000059478-26-000013

Revenue$19.3B +43% year over year
Gross profit$15.9B 83% margin
Operating profit$8.4B 43% margin
Net profit$6.6B 34% margin
100% free

It's free. All of it.

A free account opens every diagram. We send one link to confirm your address, and that is the whole of it.

Already have an account? Sign in

The numbers

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
ItemValueShare of revenueYear over year
Revenue 19.3 100% +43%
Product 18.3 95% +52%
Collaboration & other 1.0 5% −34%
Cost of revenue−3.417%
Gross profit15.983% margin+0pp
SG&A−3.116%−2pp
Other−4.423%+0pp
Operating profit8.443% margin+5pp
Interest & other costs−0.1
Tax−1.6
Net profit6.6 34% margin+2pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Source of the numbers: structured XBRL data from the filing (10-K). The diagram is generated automatically and checked against EDGAR before release. The fourth quarter has no column of its own in an annual report, so it is the full year minus the first nine months. How we calculate it → About and methodology.

123 of 418 companies, most recently reported first